Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A childhood-onset epilepsy syndrome where the onset of the condition includes manifestations of cognitive, neurological, or psychiatric impairment, stagnation, or regression, due directly to the underlying etiology. In contrast, an epileptic encephalopathy (EE) is present when the encephalopathy is caused by the epileptic activity. The term developmental and epileptic encephalopathy (DEE) is used when both factors contribute to the patient’s condition.
No HPO annotations are available for this condition.
SLC6A1-related neurodevelopmental disorder (SLC6A1-NDD) is characterized by developmental delay, epilepsy, autism spectrum disorder, and attention-deficit/hyperactivity disorder. Many individuals also have hypotonia, intermittent tremor or ataxia, and sleep disturbances . To date, more than 100 individuals have been identified with a pathogenic variant in SLC6A1 . The following description of the phenotypic features associated with this condition is based on these reports. Table 2. Select Features of SLC6A1-Related Neurodevelopmental Disorder
SLC6A1-related neurodevelopmental disorder (SLC6A1-NDD) should be considered in individuals with the following clinical findings.
Clinical findings
Mild-to-severe developmental delay (DD) and/or intellectual disability (ID)
Generalized hypotonia of infancy
No approved treatments are currently available for childhood-onset epilepsy syndrome with developmental and/or epileptic encephalopathy. The disease remains an area of unmet medical need.
No clinical practice guidelines for SLC6A1-related neurodevelopmental disorder (SLC6A1-NDD) have been published. Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with SLC6A1-NDD, the evaluations summarized (if not performed as part of the evaluation that led to diagnosis) are recommended. Table 4. Recommended Evaluations Following Initial Diagnosis in Individuals with SLC6A1-Related Neurodevelopmental Disorder
To monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations, the evaluations in are recommended.
Table 6.
Recommended Surveillance for Individuals with SLC6A1-Related Neurodevelopmental Disorder
System/Concern | Evaluation | Frequency
No clinical trials have been registered for childhood-onset epilepsy syndrome with developmental and/or epileptic encephalopathy.
302 publications have been identified in PubMed for childhood-onset epilepsy syndrome with developmental and/or epileptic encephalopathy. Research spans Review / Meta-Analysis (31%), Basic Science / Preclinical (24%), and Epidemiology / Natural History (14%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 94 |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 9:34 PM UTC
Feature | % of Persons w/Feature | Comment |
|---|---|---|
Developmental delay | 90% | Mild to severe |
Hypotonia | 60% | Low muscle tone in infancy is common improves w/age. |
Intellectual disability | 35% | Mild to severe |
Seizures | 85% | Absence atypical absence, myoclonic, atonic seizures are most prevalent. Some persons have intractable epilepsy. |
Movement disorders | 40% | Intermittent tremor w/fine motor tasks ataxia are most common. |
ASD | 30% | Rigidity, repetitive speech patterns behaviors, sensory sensitivity, sensory-seeking behaviors are most common. |
ADHD | 15% | Hyperactive, inattentive, or combined type Developmental delay (DD) is the most prevalent clinical feature, but it can vary from mild to severe among affected individuals. |
Source: GeneReviews — "SLC6A1-Related Neurodevelopmental Disorder"
Movement disorders such as tremor, stereotypies, and ataxia
Autism spectrum disorder, attention-deficit/hyperactivity disorder, aggression, anxiety, and/or sleep disturbances
Source: GeneReviews — "SLC6A1-Related Neurodevelopmental Disorder"
The phenotypic features associated with SLC6A1-related neurodevelopmental disorder (SLC6A1-NDD) are not sufficiently specific to diagnose this condition clinically; all disorders with intellectual disability and/or seizures without other distinctive findings should be considered in the differential diagnosis. See OMIM Phenotypic Series: • Autosomal Dominant Intellectual Developmental Disorder • Autosomal Recessive Intellectual Developmental Disorder • Nonsyndromic X-Linked Intellectual Developmental Disorder • Syndromic X-Linked Intellectual Developmental Disorder • Developmental and Epileptic Encephalopathy SLC6A1-NDD shares phenotypic similarities, including developmental delay, epilepsy, and autism spectrum disorder, with the disorders listed in . In particular, Rett syndrome may be considered in individuals with developmental regression, and Angelman syndrome may be considered in those with intermittent rhythmic delta activity on their EEG. Finally, sodium channelopathies (SCN1A, SCN2A, SCN8A) and GABAA receptor-related epilepsies (GABRA1, GABRB2, GABRB3, GABRG2) also have a broad phenotypic spectrum that includes epilepsy, developmental delay, and autism spectrum disorder. Table 3. Selected Genes of Interest in the Differential Diagnosis of SLC6A1-Related Neurodevelopmental Disorder
Gene(s) | Disorder | MOI | Clinical Characteristics | Comment |
|---|---|---|---|---|
GABRG2 | GABAA receptor-related epilepsies (OMIM 137160, 600232, 137192, 137164) | AD | Generalized epilepsy w/or w/o NDD. Some individuals have ASD, behavioral issues, or movement disorders. EEGs can have variable findings ranging from normal to abnormal w/focal or generalized spike-wave discharges, hypsarrhythmia, or burst-suppression pattern. Fever-related seizures are common. | Persons w/SLC6A1-NDD are unlikely to have hypsarrhythmia or burst-suppression pattern on EEG may be more likely to have NDD. |
MECP2 | Rett syndrome (See MECP2 Disorders.) | XL | Progressive NDD primarily affecting females characterized by apparently normal psychomotor development in 1st 6-18 mos of life, followed by short period of developmental stagnation, then rapid regression in language motor skills, followed by long-term stability. | Persons w/Rett syndrome typically have more severe DD/ID than those w/SLC6A1-NDD. SCN1A SCN2A |
SCN8A | Sodium channelopathies (See, e.g., SCN1A Seizure Disorders and SCN8A-Related Epilepsy w/Encephalopathy.) | AD | Epilepsy, ASD, DD. Seizures are often exacerbated by heat persons are prone to status epilepticus. May have encephalopathic features on EEG consistent w/DEE or LGS. Seizure onset is typically w/in 1st yr of life, there is risk of SUDEP. | — |
Source: GeneReviews — "SLC6A1-Related Neurodevelopmental Disorder"
Biomarker and diagnostic research for childhood-onset epilepsy syndrome with developmental and/or epileptic encephalopathy has been reported in the published literature.
System/Concern | Evaluation | Comment |
|---|---|---|
Development | Developmental assessment | To incl motor, adaptive, cognitive, speech-language eval; Eval for early intervention/ special education |
Neurologic | Neurologic eval | Consider brain MRI if neurologic exam is abnormal, if there is developmental regression, or if there are seizures.; Consider EEG if seizures are a concern.; Consider referral to a movement disorder specialist for severe tremor /or ataxia. |
Movement disorder/ Ataxia | Orthopedics/ physical medicine rehab/ PT OT eval | To incl assessment of:; Gross motor fine motor skills; Mobility, ADL, need for adaptive devices; Need for PT (to improve gross motor skills) /or OT (to improve fine motor skills) Psychiatric/ |
Behavioral | Neuropsychiatric eval | For persons age 12 mos: screening for behavior concerns incl findings suggestive of ASD, ADHD, aggression, anxiety, /or sleep disturbances Gastrointestinal/ |
Feeding | Gastroenterology/ nutrition/ feeding team eval | To incl eval of nutritional status; Assess for chronic constipation or diarrhea. |
Hearing | Audiologic eval | Assess for hearing impairment in those w/language delay.1 |
Genetic counseling | By genetics professionals2 | To inform affected persons their families re nature, MOI, implications of SLC6A1-NDD to facilitate medical personal decision making; For an online portal to aid in variant eval, click here. Family support resources |
Treatment of Manifestations in Individuals with SLC6A1-Related Neurodevelopmental Disorder Manifestation/Concern | Treatment | Considerations/Other |
Developmental delay/ Intellectual disability | See . | Epilepsy |
Bowel dysfunction | Standard treatments for constipation diarrhea | Family/Community |
Source: GeneReviews — "SLC6A1-Related Neurodevelopmental Disorder"
Given the high prevalence of challenging behaviors in individuals with SLC6A1-NDD, levetiracetam should be used with caution. Individuals with SLC6A1-NDD have intolerable behavioral side effects with levetiracetam at higher rates than reported in the general population.
Source: GeneReviews — "SLC6A1-Related Neurodevelopmental Disorder"
There are therapies for SLC6A1-NDD in development. To date, one clinical trial is assessing the safety and efficacy of 4-phenylbutyrate in individuals with SLC6A1-NDD (NCT04937062). Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions.
Source: GeneReviews — "SLC6A1-Related Neurodevelopmental Disorder"
View trials for childhood-onset epilepsy syndrome with developmental and/or epileptic encephalopathy
Physical medicine OT/PT assessment of mobility self-help skills
| At each visit
| • Monitor those w/seizures as clinically indicated.
Assess for new manifestations such as seizures, changes in tone, movement disorders.
Psychiatric/
| Behavioral assessment for findings suggestive of ASD, ADHD, aggression, self-injury, anxiety, /or sleep disturbances
| Monitor for constipation or diarrhea.
| Assess family need for social work support (e.g., palliative/respite care, home nursing, other local resources), care coordination, or follow-up genetic counseling if new questions arise (e.g., family planning).
ADHD = attention-deficit/hyperactivity disorder; ASD = autism spectrum disorder; OT = occupational therapy; PT = physical therapy
Source: GeneReviews — "SLC6A1-Related Neurodevelopmental Disorder"
Laboratory research | 73 | 24% |
Disease patterns and progression | 42 | 14% |
Patient case studies | 37 | 12% |
New treatment approaches | 19 | 6% |
Testing and diagnosis research | 18 | 6% |
Clinical study results | 18 | 6% |
Other research | 1 | 0% |
Whyte-Fagundes P (2026). [PMID: 41118267](https://pubmed.ncbi.nlm.nih.gov/41118267/). *Epilepsia*. [Basic Science / Preclinical]
Gélisse P (2026). [PMID: 41391422](https://pubmed.ncbi.nlm.nih.gov/41391422/). *Seizure*. [Review / Meta-Analysis]
Brünger T (2026). [PMID: 41822692](https://pubmed.ncbi.nlm.nih.gov/41822692/). *medRxiv*. [Gene Therapy / Novel Therapeutics]
Bidwell JS (2026). [PMID: 41250984](https://pubmed.ncbi.nlm.nih.gov/41250984/). *Epilepsia Open*. [Epidemiology / Natural History]
Dlugos DJ (2026). [PMID: 41133912](https://pubmed.ncbi.nlm.nih.gov/41133912/). *Epilepsia*. [Clinical Trial Publication]
Song ZD (2026). [PMID: 42239367](https://pubmed.ncbi.nlm.nih.gov/42239367/). *bioRxiv*. [Diagnostic / Biomarker]
Perilli L (2026). [PMID: 41914479](https://pubmed.ncbi.nlm.nih.gov/41914479/). *Expert Rev Clin Pharmacol*. [Review / Meta-Analysis]
Riva A (2026). [PMID: 41159734](https://pubmed.ncbi.nlm.nih.gov/41159734/). *Epilepsia*. [Review / Meta-Analysis]
Dahshi H (2026). [PMID: 41893060](https://pubmed.ncbi.nlm.nih.gov/41893060/). *Neurol Int*. [Diagnostic / Biomarker]
Qi L (2026). [PMID: 41560101](https://pubmed.ncbi.nlm.nih.gov/41560101/). *Medicine (Baltimore)*. [Epidemiology / Natural History]